Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Issa Khouri, Roland L Bassett, Yvonne Hsu, Timothy Dickason, Sandra Acholonu, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Martin J. Korbling, Amin M. Alousi, Chitra Hosing, Uday Popat, Sergio A. Giralt, Partow Kebriaei, Muzaffar H. Qazilbash, M.D., Celina Ledesma, Michael J. Keating, MB, BS, Richard E. Champlin, Carlos Bueso-Ramos

Blood (2008) 112 (11): 1128.

https://doi.org/10.1182/blood.V112.11.1128.1128

Published: 2008

Journal Articles

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Blood (2008) 112 (11): 1142.

https://doi.org/10.1182/blood.V112.11.1142.1142

Published: 2008

Journal Articles

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

Blood (2006) 108 (11): 315.

https://doi.org/10.1182/blood.V108.11.315.315

Published: 2006

Journal Articles

Non-Myeloablative Allogeneic Transplantation (NMT) with T-Cell Replete Graft for Relapsed Chemosensitive Follicular Lymphoma (FL): Donor Lymphocyte Infusion (DLI) To Convert Stable Mixed Chimerism to Full Donor Chimerism Is Not Necessary in the Absence of Disease Progression.

Issa F. Khouri, MD, Ming-Sheng Lee, MD, Rima M. Saliba, PhD, Sandra A. Acholonu, Rosamar Valverde, Martin J. Korbling, MD, Ricahrd E. Champlin, MD

Blood (2005) 106 (11): 3659.

https://doi.org/10.1182/blood.V106.11.3659.3659

Published: 2005

Journal Articles

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

Issa F. Khouri, MD, Rima M. Saliba, PhD, Chitra M. Hosing, MD, Sandra A. Acholonu, MPH, Luis E. Fayad, MD, Martin J. Korbling, MD, Celina Saenz, BS, Barbara Pro, MD, Barry I. Samuels, MD, Marcos J. de Lima, MD, Sergio A. Giralt, MD, Anas Younes, MD, Peter W. McLaughlin, MD, Richard E. Champlin, MD

Blood (2005) 106 (11): 48.

https://doi.org/10.1182/blood.V106.11.48.48

Published: 2005

Journal Articles

A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).

James L. Gajewski, MD, Rima Saliba, PhD, John D. McMannis, PhD, Elizabeth J. Shpall, MD, Cindy Ippoliti, MD, Sergio A. Giralt, MD, Roy B. Jones, MD, Issa F. Khouri, MD, Chitra M. Hosing, MD, Martin J. Korbling, MD, Michele L. Donato, MD, Richard E. Champlin, MD

Blood (2004) 104 (11): 5184.

https://doi.org/10.1182/blood.V104.11.5184.5184

Published: 2004

NARROW

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

Non-Myeloablative Allogeneic Transplantation (NMT) with T-Cell Replete Graft for Relapsed Chemosensitive Follicular Lymphoma (FL): Donor Lymphocyte Infusion (DLI) To Convert Stable Mixed Chimerism to Full Donor Chimerism Is Not Necessary in the Absence of Disease Progression.

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).

Email alerts

ASH Publications

American Society of Hematology

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

Non-Myeloablative Allogeneic Transplantation (NMT) with T-Cell Replete Graft for Relapsed Chemosensitive Follicular Lymphoma (FL): Donor Lymphocyte Infusion (DLI) To Convert Stable Mixed Chimerism to Full Donor Chimerism Is Not Necessary in the Absence of Disease Progression.

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only